Recent studies in Korea have explored the impact of medical conditions and treatments on long-term health outcomes, revealing significant insights into the management of hepatocellular carcinoma (HCC) and steatotic liver disease (SLD) and their implications for cardiovascular disease (CVD) risk. One study focused on the association between statin use and the prognosis of HCC patients post-hepatic resection, finding that statin users experienced notably improved recurrence-free survival (RFS) and overall survival (OS), especially among non-cirrhotic patients, those with larger tumors, or tumors with microscopic vascular invasion. This research underscores a duration-response relationship, suggesting a potential therapeutic role for statins in HCC patient management post-surgery. Another investigation examined the link between different subtypes of SLD—specifically metabolic dysfunction-associated steatotic liver disease (MASLD), MASLD with increased alcohol intake (MetALD), and alcohol-related liver disease (ALD)—and the risk of developing CVD. It was found that all SLD subtypes were associated with an elevated risk of CVD, highlighting the additive impact of alcohol consumption on cardiometabolic risk factors. These findings collectively emphasize the importance of tailored medical interventions and the need for precise clinical assessments in improving long-term health outcomes for patients with liver conditions, while also pointing to the broader implications of liver health on cardiovascular risk.